Charlotte Robinson

DocwireNews

The phase 2b ORIGIN study compared randomized groups of patients with IgA nephropathy (IgAN) receiving either atacicept or placebo. Richard Lafayette and others shared interim analysis results at the 61st European Renal Association Congress.Atacicept targets B-cell activating factor and a proliferation-inducing ligand (APRIL), both of which drive production of galactose-deficient IgA1 (Gd-IgA1) and its antibodies. Elevated Gd-IgA1 is the hallmark of IgAN.ORIGIN included 116 participants with 24-hour urine protein &gt;0.75 g/day or urine protein-to-creatine ratio (UPCR) &gt;0.75 g/g and estimated glomerular filtration rate (eGFR) &ge;30 mL/min/1.73 m2 despite optimized treatment with renin-angiotensin system (RAS) blockade. The double-blind study randomized them to receive atacicept 150, 75, or 25 mg versus placebo (2:2:1:2) for up to 36 weeks. During a subsequent open-label extension period, participants could receive atacicept 150 mg for up to 60 additional weeks.Of the 116 participants, 106 (91%) finished 72 weeks of treatment. At 72 weeks, atacicept achieved statistically significant eGFR stability and reduction in UPCR and Gd-IgA1 compared with placebo.The eGFR change from baseline at 72 weeks was 0 mL/min/1.73 m2 in all participants originally randomized to atacicept (all-atacicept group; n=82). After the placebo group switched to atacicept 150 mg, individuals in that group showed eGFR stabilization with &minus;3.2 mL/min/1.73 m2 change from baseline at 72 weeks compared with &minus;4.9 mL/min/1.73 m2 at 36 weeks. Atacicept 150 mg was also associated with quick Gd-IgA1 reduction in the group that switched from placebo at 48 weeks, and the reduction was sustained through 72 weeks.At 72 weeks, UPCR change from baseline was &minus;45% in the all-atacicept group, while the placebo switch group demonstrated a &minus;47% UPCR change from baseline at 72 weeks versus +3% at 36 weeks. Hematuria resolution occurred in 81% (35/43) of participants in the all-atacicept group at 72 weeks and 59% (10/17) in the placebo switch group.In addition to the clinical benefits observed, atacicept was well-tolerated and demonstrated safety comparable with the placebo.Source: Lafayette R, Maes R, Israni R, et al. <a href="https://doi.org/10.1093/ndt/gfae069.030" target="_blank" rel="noopener">Phase 2b ORIGIN study open label extension with atacicept in patients with IgA nephropathy and persistent proteinuria: week 72 interim analysis.</a> Abstract #812. Presented at the 61st European Renal Association Congress; May 23-26, 2024; Stockholm, Sweden.

Eva Blondeaux, MD

Risk-Reducing Surgery Linked to Survival in Young BRCA Carriers

Genetics & Breast Cancer

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

Latest News

ORIGIN Study of Atacicept for IgA Nephropathy

ERA Congress 2024

At the 61st European Renal Association (ERA) Congress, researchers shared interim results from the ORIGIN study of atacicept in patients with IgA nephropathy (IgAN).

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe